Unlike prior EGFR-TKI generations, osimertinib selectively and irreversibly binds to EGFR-mutants inhibiting downstream signaling pathways and ultimately preventing tumor cell proliferation while promoting apoptosis [22]. This evidence concerns the gene EGFR and neoplasm.